{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T01:08:31Z","timestamp":1774314511060,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,2]]},"DOI":"10.7759\/cureus.98324","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T17:55:42Z","timestamp":1764698142000},"source":"Crossref","is-referenced-by-count":1,"title":["Immune-Related Esophagitis and Durable Response to Second-Line Treatment With Nivolumab in Stage IV Squamous Cell Esophageal Carcinoma"],"prefix":"10.7759","author":[{"given":"Olga","family":"Meneses","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Alzamora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Dias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Ortig\u00e3o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D\u00e2nia","family":"Marques","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021, 71:209-49. 10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.05.054","article-title":"The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: New estimates from GLOBOCAN 2020","volume":"163","author":"Morgan E","year":"2022","unstructured":"Morgan E, Soerjomataram I, Rumgay H, et al.. The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: New estimates from GLOBOCAN 2020. Gastroenterology. 2022, 163:649-658.e2. 10.1053\/j.gastro.2022.05.054","journal-title":"Gastroenterology"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw329","article-title":"Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Lordick F","year":"2016","unstructured":"Lordick F, Mariette C, Haustermans K, Obermannov\u00e1 R, Arnold D. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016, 27:v50-7. 10.1093\/annonc\/mdw329","journal-title":"Ann Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30626-6","article-title":"Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION- 3): A multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Kato K","year":"2019","unstructured":"Kato K, Cho BC, Takahashi M, et al.. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION- 3): A multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019, 20:1506-17. 10.1016\/S1470-2045(19)30626-6","journal-title":"Lancet Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-018-2819-x","article-title":"Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma","volume":"145","author":"Indini A","year":"2019","unstructured":"Indini A, Di Guardo L, Cimminiello C, Prisciandaro M, Randon G, De Braud F, Del Vecchio M. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma. J Cancer Res Clin Oncol. 2019, 145:511-21. 10.1007\/s00432-018-2819-x","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2018.08.008","article-title":"Incidence, risk factors, and effect on survival of immune-related adverse events in patients with non-small-cell lung cancer","volume":"19","author":"Owen DH","year":"2018","unstructured":"Owen DH, Wei L, Bertino EM, et al.. Incidence, risk factors, and effect on survival of immune-related adverse events in patients with non-small-cell lung cancer. Clin Lung Cancer. 2018, 19:e893-900. 10.1016\/j.cllc.2018.08.008","journal-title":"Clin Lung Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0579-z","article-title":"Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: The Italian expanded access program","volume":"7","author":"Verzoni E","year":"2019","unstructured":"Verzoni E, Carten\u00ec G, Cortesi E, et al.. Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: The Italian expanded access program. J Immunother Cancer. 2019, 7:99. 10.1186\/s40425-019-0579-z","journal-title":"J Immunother Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.180870","article-title":"Adverse events associated with immune checkpoint inhibitor treatment for cancer","volume":"191","author":"Esfahani K","year":"2019","unstructured":"Esfahani K, Meti N, Miller WH Jr, Hudson M. Adverse events associated with immune checkpoint inhibitor treatment for cancer. CMAJ. 2019, 191:E40-6. 10.1503\/cmaj.180870","journal-title":"CMAJ"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen J","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, et al.. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022, 33:1217-38. 10.1016\/j.annonc.2022.10.001","journal-title":"Ann Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.21037\/jgo-22-281","article-title":"Immune-related adverse events and prognosis in patients with upper gastrointestinal cancer treated with nivolumab","volume":"13","author":"Hara Y","year":"2022","unstructured":"Hara Y, Baba Y, Toihata T, et al.. Immune-related adverse events and prognosis in patients with upper gastrointestinal cancer treated with nivolumab. J Gastrointest Oncol. 2022, 13:2779-88. 10.21037\/jgo-22-281","journal-title":"J Gastrointest Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16203529","article-title":"Relationship of immune-related adverse events with tumor response and prognosis in esophageal squamous cell carcinoma following nivolumab monotherapy","volume":"16","author":"Hamai Y","year":"2024","unstructured":"Hamai Y, Ibuki Y, Kurokawa T, et al.. Relationship of immune-related adverse events with tumor response and prognosis in esophageal squamous cell carcinoma following nivolumab monotherapy. Cancers. 2024, 16:3529. 10.3390\/cancers16203529","journal-title":"Cancers"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.5893-20","article-title":"A durable response after the discontinuation of nivolumab in an advanced gastric cancer patient","volume":"60","author":"Yatsuda Y","year":"2021","unstructured":"Yatsuda Y, Hirose S, Ito Y, et al.. A durable response after the discontinuation of nivolumab in an advanced gastric cancer patient. Intern Med. 2021, 60:1011-7. 10.2169\/internalmedicine.5893-20","journal-title":"Intern Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.7675","article-title":"Clinicopathologic features, treatment response, and outcomes of immune checkpoint inhibitor-related esophagitis","volume":"19","author":"Panneerselvam K","year":"2021","unstructured":"Panneerselvam K, Amin RN, Wei D, et al.. Clinicopathologic features, treatment response, and outcomes of immune checkpoint inhibitor-related esophagitis. J Natl Compr Canc Netw. 2021, 19:896-904. 10.6004\/jnccn.2020.7675","journal-title":"J Natl Compr Canc Netw"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2020-0070-RA","article-title":"Pathologic manifestations of gastrointestinal and hepatobiliary injury in immune checkpoint inhibitor therapy","volume":"145","author":"Patil PA","year":"2021","unstructured":"Patil PA, Zhang X. Pathologic manifestations of gastrointestinal and hepatobiliary injury in immune checkpoint inhibitor therapy. Arch Pathol Lab Med. 2021, 145:571-82. 10.5858\/arpa.2020-0070-RA","journal-title":"Arch Pathol Lab Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2019.1594356","article-title":"Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors","volume":"54","author":"Tang T","year":"2019","unstructured":"Tang T, Abu-Sbeih H, Luo W, et al.. Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors. Scand J Gastroenterol. 2019, 54:538-45. 10.1080\/00365521.2019.1594356","journal-title":"Scand J Gastroenterol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0481-0","article-title":"A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy","volume":"6","author":"Horisberger A","year":"2018","unstructured":"Horisberger A, La Rosa S, Zurcher JP, Zimmermann S, Spertini F, Coukos G, Obeid M. A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy. J Immunother Cancer. 2018, 6:156. 10.1186\/s40425-018-0481-0","journal-title":"J Immunother Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/429773-immune-related-esophagitis-and-durable-response-to-second-line-treatment-with-nivolumab-in-stage-iv-squamous-cell-esophageal-carcinoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T17:55:43Z","timestamp":1764698143000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/429773-immune-related-esophagitis-and-durable-response-to-second-line-treatment-with-nivolumab-in-stage-iv-squamous-cell-esophageal-carcinoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.98324","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,2]]}}}